SHR-3045
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 11
Of
11
Go to page
1
June 12, 2026
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=16 | Completed | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting ➔ Completed
Trial completion • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
June 06, 2026
A Phase Ⅰ Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=40 | Completed | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Active, not recruiting ➔ Completed
Trial completion • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
May 02, 2026
SHR-3045-201: A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis
(clinicaltrials.gov)
- P2 | N=30 | Active, not recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting ➔ Active, not recruiting
Enrollment closed • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
January 30, 2026
SHR-3045-201: A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis
(clinicaltrials.gov)
- P2 | N=30 | Recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
November 19, 2025
A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis
(clinicaltrials.gov)
- P2 | N=30 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
New P2 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
November 18, 2025
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=16 | Recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
October 02, 2025
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=16 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
New P1 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
September 19, 2025
Jiangsu Hengrui Pharmaceuticals…announced that China’s National Medical Products Administration (NMPA) has granted approval for clinical trials of two independently developed biologics: SHR‑3045 injection for rheumatoid arthritis (RA) and SHR‑1139 injection for ulcerative colitis (UC)
(flcube.com)
New trial • Rheumatoid Arthritis • Ulcerative Colitis
August 13, 2025
A Phase Ⅰ Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=40 | Active, not recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting ➔ Active, not recruiting
Enrollment closed • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
April 26, 2025
A Phase Ⅰ Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
March 19, 2025
A Phase Ⅰ Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
New P1 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
1 to 11
Of
11
Go to page
1